share_log

Earnings Call Summary | YS Biopharma(YS.US) Q3 2024 Earnings Conference

Earnings Call Summary | YS Biopharma(YS.US) Q3 2024 Earnings Conference

業績電話會議摘要 | YS Biopharma (YS.US) 2024 年第三季度業績會議
富途資訊 ·  04/19 21:16  · 電話會議

The following is a summary of the YS Biopharma Co., Ltd. (YS) Q3 2024 Earnings Call Transcript:

以下是美國生物製藥有限公司（YS）2024年第三季度業績電話會議記錄摘要：

Financial Performance:

財務業績：

  • YS Biopharma reported a total revenue of RMB 438.1 million for the first nine months of fiscal year 2024, a year-over-year decrease by 24.6% due to supply chain disruptions.

  • Net loss of RMB 260 million was recorded for the same period.

  • The company projects double-digit growth in product sales for the end of fiscal year 2024 and throughout 2025.

  • YS Biopharma報告稱，2024財年前九個月的總收入爲4.381億元人民幣，由於供應鏈中斷，同比下降24.6％。

  • 同期淨虧損爲人民幣2.6億元。

  • 該公司預計，到2024財年末和整個2025年，產品銷售將實現兩位數的增長。

Business Progress:

業務進展：

  • YS Biopharma successfully addressed inventory issues and balanced their strategy to meet market demands.

  • The company continues to strengthen relationships with CDC customers in China, constituting more than 6% of their network.

  • Priority placed on pre-clinical and clinical pipeline across all subsidiaries in the US, China, and Singapore.

  • Successful results from the Phase III trial of their PIKA rabies vaccine show potential for faster production and improved regimen.

  • The company plans to conduct a Phase 1 study for their Hepatitis B vaccine.

  • YS Biopharma成功解決了庫存問題並平衡了戰略以滿足市場需求。

  • 該公司繼續加強與中國CDC客戶的關係，佔其網絡的6％以上。

  • 優先考慮美國、中國和新加坡所有子公司的臨床前和臨床產品線。

  • 他們的PIKA狂犬病疫苗三期試驗的成功結果表明，有可能加快生產速度和改善治療方案。

  • 該公司計劃對其乙型肝炎疫苗進行1期研究。

Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.

提示：欲了解更多詳情，請訪問投資者關係網站。本文僅供投資者參考，不構成任何投資建議。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論